First human trial for gene therapy targeting rare heart disease
NCT ID NCT07426419
Summary
This early-stage trial is testing a new, single-dose gene therapy called AFTX-201 for adults with a specific inherited form of heart failure. The main goal is to see if the treatment is safe and well-tolerated. Researchers will also look for early signs that it might improve heart function and quality of life in participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.